Kineta (Kineta) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Kineta FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kineta's Free Cash Flow for the three months ended in Dec. 2023 was $-4.08 Mil. Kineta's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Kineta's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Kineta's current FCF Yield % is -280.00%.

The historical rank and industry rank for Kineta's FCF Margin % or its related term are showing as below:

KA' s FCF Margin % Range Over the Past 10 Years
Min: -1834.77 Med: -247.12 Max: 21.83
Current: -297.85

During the past 4 years, the highest FCF Margin % of Kineta was 21.83%. The lowest was -1834.77%. And the median was -247.12%.

KA's FCF Margin % is ranked worse than
59.37% of 1041 companies
in the Biotechnology industry
Industry Median: -145.04 vs KA: -297.85

Kineta FCF Margin % Historical Data

The historical data trend for Kineta's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta FCF Margin % Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

21.83

-196.38

-1,834.77

-297.85

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial						1,763.06	-1,758.01	-134.95	-	-

Competitive Comparison of Kineta's FCF Margin %

For the Biotechnology subindustry, Kineta's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kineta's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kineta's FCF Margin % falls into.

Kineta FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kineta's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16.209	/	5.442
	=	-297.85 %

Kineta's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.075	/	0
	=	%

Kineta FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kineta's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta (Kineta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (NAS:KA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

J75:Germany

Address

219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Executives

Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky	director	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust	10 percent owner	C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust	10 percent owner	C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109